Neuropathology Core

马萨诸塞州阿尔茨海默病研究中心：神经病理学核心 神经病理学核心服务于马萨诸塞州 ADRC (MADRC) 和阿尔茨海默病研究 通过提供临床评估的诊断验证并向研究人员提供组织来社区。 神经病理学评估有助于理解与 AD/ADRD 相关的异质性， 跨疾病和并发病理过程。核心组织的可用性 已被致力于加速 AD/ADRC 治愈的研究人员广泛使用。为了完成这些 使命，我们有三组目标。 第一组（目标 1-3）旨在整合资源，重点是收集、诊断、 收集数据，向家属和相关医生全面报告结果，并进行符合 CLIA 的尸检 通过临床核心报告，并出于研究目的向数据核心报告——以及广泛分布 支持研究界的样品。这些努力直接解决了异质性问题。 第二组（目标 4-6）旨在制定新战略，纳入创新方法 确定 AD/ADRD 影像学和液体生物标志物的神经病理学基础，定义 AD/ADRD 临床试验受试者的神经病理学发现，并开发新的细胞资源 尸检组织，包括 iPSC（将存放在 NCRAD）和分离的细胞类型特异性细胞核。正如这些 制定三个目标后，我们将与其他 ADC 分享见解并合作进行验证和广泛应用 实施。疾病异质性将在生物标志物基础的评估中得到解决 信号和临床试验受试者的评估。 最后一组（目标 7 和 8）旨在建设未来，重点关注培训。首先，有一个 AD/ADRD 神经病理学方面的基础和临床研究人员培训的组成部分 基于组织的研究的复杂性和问题。这些努力将与以下机构密切合作进行： 记录。还与 ORE Core 合作，在广泛的教育方面做出了努力 尸检和大脑捐赠对于加强我们解决 AD/ADRD 问题的努力非常重要。 Neuropath 核心与 MADRC 的所有其他组成部分以及更广泛的科学领域相互作用 社区解决关键问题，加速 AD/ADRD 的治愈。

Massachusetts Alzheimer’s Disease Research Center: Neuropathology Core The Neuropathology Core serves both the Massachusetts ADRC (MADRC) and the Alzheimer research community by providing diagnostic validation of clinical assessments and providing tissue to investigators. Neuropathologic assessment has contributed to understanding heterogeneity associated with AD/ADRD, both across diseases and in terms of concurrent pathologic processes. The availability of tissue from the Core has been widely used by investigators working to accelerate toward a cure for AD/ADRC. To complete these missions, we have three sets of Aims. The first group (Aims 1-3), which are intended to marshal resources, is focused on the collection, diagnosis, collection of data, full reporting of findings – to families and relevant physicians with a CLIA-compliant autopsy report through the Clinical Core, and to the Data Core for research purposes -- and the wide distribution of samples in support of the research community. Issues of heterogeneity are directly addressed in these efforts. The second group (Aims 4-6), which are intended to develop new strategies, incorporate innovate methods to determine the neuropathologic basis of imaging and fluid biomarkers in AD/ADRD, define the neuropathologic findings in subjects from clinical trials for AD/ADRD and develop new cellular resources from autopsy tissue including iPSCs (to be deposited at NCRAD) and isolated cell-type specific nuclei. As these three aims develop, we will be sharing insights and collaborating with other ADCs for validation and broad implementation. Disease heterogeneity will be addressed in both the assessment of the basis of biomarker signals and in the assessment of clinical trials subjects. The final group (Aims 7 & 8), which are intended to build the future, focus on training. First, there is a component of training basic and clinical researchers in aspects of the neuropathology of AD/ADRD as well as the intricacies and issues around tissue-based research. These efforts will be done in close collaboration with the REC. There are also efforts, done in collaboration with the ORE Core, in broad education about the importance of autopsy and brain donation to enhance our efforts to tackle AD/ADRD. The Neuropath Core interacts with all other components of the MADRC and with the broader scientific community to address critical problems to accelerate towards a cure for AD/ADRD.